Otsuka Holdings Co. (OTSKY) 16.2400 $OTSKY
ReCor Medical Announces New Lead Investor and Upcoming Hypertension Trial
PR Newswire Europe - Fri Apr 10, 12:54PM CDT
ReCor Medical, Inc., a Palo Alto- and Amsterdam-based medical device firm, announced today a Series D investment of approximately $15M led by Otsuka Holdings Co., Ltd., the parent company of Otsuka Pharmaceutical and the Otsuka group of healthcare companies. Otsuka Holdings, one of the leading healthcare groups in Japan, joined Sofinnova Partners in the Series D round. In addition, ReCor has met with the US FDA regarding a new randomized controlled trial of its Paradise Renal Denervation ("RDN"
System in hypertensive patients to demonstrate its effect on blood pressure in conjunction with, and in the absence of, hypertensive drug therapy. The Company is planning to conduct the new study at 20 - 25 sites in the US and EU.
BSX: 18.10 (unch)
Is Biogen A Buy? An Analysis Of Its Growth Drivers And Challenges
DoctoRx - at Seeking Alpha - Thu Apr 09, 12:28AM CDT
BIIB: 425.65 (-0.98), MDCO: 28.31 (+0.49), GILD: 101.77 (+0.61), MRK: 57.25 (-0.18), AZN: 69.91 (-0.25), LLY: 73.92 (+1.56), ABBV: 62.00 (+1.68), CELG: 117.07 (+1.49)
Polycystic Kidney Disease Global Clinical Trials Review, H1, 2015
M2 - Tue Mar 31, 4:15AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zf6s4z/polycystic_kidney) has announced the addition of the "Polycystic Kidney Disease Global Clinical Trials Review, H1, 2015" report to their offering. Polycystic Kidney Disease Global Clinical Trials Review, H1, 2015" provides data on the Polycystic Kidney Disease clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Polycystic Kidney Disease. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Polycystic Kidney Disease. Reasons to buy - Understand the dynamics of a particular indication in a condensed manner - Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more - Obtain discontinued trial listing for trials across the globe - Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies Top Companies Participating in Polycystic Kidney Disease Therapeutics Clinical Trials - Otsuka Holdings Co., Ltd. - Pfizer Inc. - Kadmon Corporation, LLC - Daiichi Sankyo Company, Limited - XORTX Pharma Corp. - Novartis AG - GLG Pharma LLC For more information visit http://www.researchandmarkets.com/research/zf...tic_kidney
PFE: 35.44 (+0.41), NVS: 103.58 (+1.01)
Type 1 Diabetes, Progress With Stem Cells And Other Cell-Based Therapies
Keith Williams - at Seeking Alpha - Mon Mar 30, 2:05PM CDT
NVO: 55.94 (+1.34), AZN: 69.91 (-0.25), BMY: 64.64 (+1.18)
2015 could be the year of the blockbuster drug
Seeking Alpha - at Seeking Alpha - Mon Mar 23, 3:26PM CDT
VRTX: 128.47 (+2.83), PFE: 35.44 (+0.41), AMGN: 163.38 (+1.89), BMY: 64.64 (+1.18), GSK: 48.23 (+0.51), GILD: 101.77 (+0.61), MRK: 57.25 (-0.18), ABBV: 62.00 (+1.68), THRX: 17.13 (+0.37), SNY: 52.35 (+0.48), REGN: 461.39 (+6.35), NVS: 103.58 (+1.01)
CHMP supports approval of Otsuka kidney disease drug
Seeking Alpha - at Seeking Alpha - Fri Feb 27, 10:19AM CST
Glaucoma Therapeutic Pipeline Companies and Drugs Review H1 2015 Report at RnRMarketResearch.com
PRWeb - Sun Jan 25, 11:30AM CST
The report "Glaucoma - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Glaucoma. Glaucoma is caused because of the pressure inside the eye. The primary function of the optic nerve is to send images to the brain. Permanent loss of vision can occur if this optic nerve gets damaged. If not treated on time total permanent blindness might occur. Proper precautions (like visiting an eye doctor) must be taken. The disease can be inherited and if any member of the family is found to be having glaucoma then immediately go for checking. Complete Report is Available @ http://www.rnrmarketresearch.com/glaucoma-pip...eport.html .
OCAT: 6.63 (-0.03), ITEK: 5.12 (-0.09), NBS: 2.98 (+0.06), FOMX: 9.87 (+0.45), AERI: 32.30 (+0.14), OCUL: 26.99 (-1.55), AGN: 240.22 (+2.88), CANF: 2.18 (+0.07), ACAD: 37.53 (+2.42), GILD: 101.77 (+0.61), MRK: 57.25 (-0.18), TEVA: 66.37 (-0.77), OHRP: 2.80 (+0.11), CBMG: 28.95 (+1.47)
Autism Therapeutic Pipeline Drugs and Companies Review H1 2015 Report at RnRMarketResearch.com
PRWeb - Fri Jan 23, 6:36AM CST
The report "Autism - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Autism. Autism is known as a multifarious developmental disability. Autism disorder is characterized by social activities, non-verbal communication and repetitive behavior. Autism is highly transmissible but the cause includes both environmental factors and genetic susceptibility. It has long been assumed that there is a common cause at the genetic, cognitive and neural levels for autism's characteristic triad of symptoms. The report enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Complete Report is Available @ http://www.rnrmarketresearch.com/autism-pipel...eport.html .
TEVA: 66.37 (-0.77), ITCI: 23.98 (+0.15), BCLI: 4.63 (+0.31), OMER: 24.58 (+0.44), NVS: 103.58 (+1.01)
Avanir's Drug-Device Combo Experiencing Minor FDA Headaches
Beacon VP Investments - at Seeking Alpha - Mon Dec 22, 1:41PM CST
AVNR: 16.96 (unch)
New Bidders Can Bring You High Return: Otsuka To Acquire Avanir
Maudes Capital - at Seeking Alpha - Tue Dec 02, 12:51PM CST
AVNR: 16.96 (unch)
Otsuka to buy US drugmaker Avanir for $3.5B
By The Associated Press - AP - Tue Dec 02, 6:06AM CST
Otsuka Pharmaceutical will spend $3.5 billion in cash to buy Avanir Pharmaceuticals in a deal that expands the Japanese drugmaker's portfolio of neurologic disease treatments.
AVNR: 16.96 (unch)
Wall Street Breakfast: Apple Heads To Trial Over iTunes Update
Wall Street Breakfast - Seeking Alpha - Tue Dec 02, 5:32AM CST
Economy Chinese stocks staged a late rally today amid speculation of more stimulus from the country's central bank. The Shanghai Composite Index climbed 3.1% , while the Hang Seng benchmark rose 1.2% . Oil has resumed declines as commodity...
VTNR: 2.58 (+0.03), MDT: 77.93 (+0.80), AV: 16.35 (+0.03), TFM: 41.47 (+0.47), GLW: 22.42 (+0.18), BA: 154.38 (+0.96), PCLN: 1,189.50 (+3.50), AVNR: 16.96 (unch), PERY: 24.56 (-0.01), SPY: 210.04 (+1.14), QQQ: 107.75 (+0.44), MSFT: 41.72 (+0.24), HMC: 34.66 (+0.58), AAPL: 127.10 (+0.54), HLSS: 17.18 (+0.01)
Otsuka to acquire Avanir for $17/share
Seeking Alpha - at Seeking Alpha - Tue Dec 02, 2:44AM CST
AVNR: 16.96 (unch)
Global Chronic Kidney Disease (Chronic Renal Failure) Therapeutics Pipeline Report H2 2014 - Analysis of 27 Companies & 39 Drug Profiles
M2 - Mon Nov 10, 10:32AM CST
Research and Markets (http://www.researchandmarkets.com/research/n5l8s3/chronic_kidney) has announced the addition of the "Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Kidney Disease (Chronic Renal Failure), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Kidney Disease (Chronic Renal Failure) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Hospira, Inc. - AstraZeneca PLC - Eli Lilly and Company - Quark Pharmaceuticals, Inc. - Astellas Pharma Inc. - OPKO Health, Inc. - Toray Industries, Inc. - Evotec AG - NPS Pharmaceuticals, Inc. - La Jolla Pharmaceutical Company - Alexion Pharmaceuticals, Inc. - AFFiRiS AG - Acceleron Pharma, Inc. - Nippon Zoki Pharmaceutical Co., Ltd. - Catabasis Pharmaceuticals, Inc. - Angion Biomedica Corp. - Concert Pharmaceuticals, Inc. - Intercept Pharmaceuticals, Inc. - Vitae Pharmaceuticals, Inc. - TRACON Pharmaceuticals, Inc. - Stelic Institute & Co. - Vicore Pharma AB - Otsuka Holdings Co., Ltd. - Sphaera Pharma Pvt. Ltd. - Multi Gene Vascular Systems Ltd - Bio-inRen - Red Glead Discovery AB For more information visit http://www.researchandmarkets.com/research/n5...nic_kidney
VTAE: 15.57 (+0.06), LLY: 73.92 (+1.56), CNCE: 14.71 (-0.41), OPK: 14.25 (-0.01), AZN: 69.91 (-0.25), ALXN: 182.68 (+5.31), ICPT: 279.25 (+7.48), NPSP: 45.97 (+0.01), XLRN: 34.23 (+0.15)
Global Bipolar Disorder (Manic Depression) Therapeutics Pipeline Review, H2 2014 - 22 Companies & 30 Drug Profiles
M2 - Thu Nov 06, 3:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/6grxbp/bipolar_disorder) has announced the addition of the "Bipolar Disorder (Manic Depression) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Bipolar Disorder (Manic Depression), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bipolar Disorder (Manic Depression) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AstraZeneca PLC - Eli Lilly and Company - Sumitomo Dainippon Pharma Co., Ltd. - Takeda Pharmaceutical Company Limited - Zogenix, Inc. - Richter Gedeon Nyrt. - Pfizer Inc. - Teva Pharmaceutical Industries Limited - Transition Therapeutics Inc. - Intas Pharmaceuticals Ltd. - D-Pharm Ltd. - Omeros Corporation - Intra-Cellular Therapies, Inc. - KemPharm, Inc. - Ascendis Pharma A/S - Otsuka Holdings Co., Ltd. - Reviva Pharmaceuticals Inc. - MarcoPolo Pharmaceuticals SA - Delpor, Inc. - Zysis Limited - Convergence Pharmaceuticals Ltd. - SK Biopharmaceuticals Co., Ltd. Drug Profiles - aripiprazole - quetiapine fumarate ER - ramelteon - ELND-005 - ziprasidone hydrochloride - cariprazine - YKP-3089 - Endoxifen - ITI-007 - DP-VPA - LY-2979165 - risperidone - Drug for Cancer and Neurodegenerative Disease - aripiprazole CR - lurasidone hydrochloride - SKL-PSY - Small Molecule To Antagonize GPR78 for Bipolar Disorder and Schizophrenia - NP-202 - ACP-005 - Small Molecule to Target GPR50 for CNS and Metabolic Disorders - risperidone - paliperidone - CNV-1061436 - PGW-5 - KP-303 - MP-03 - Small Molecules to Antagonize NMDA Receptor and CHRNA7 for CNS - Synthetic Peptides to inhibit IMPase for Bipolar Disorder - BRDK-98958073 - RP-5063 For more information visit http://www.researchandmarkets.com/research/6g...r_disorder
ZGNX: 1.49 (+0.01), PFE: 35.44 (+0.41), AZN: 69.91 (-0.25), TTHI: 6.99 (+0.08), TEVA: 66.37 (-0.77), ITCI: 23.98 (+0.15), LLY: 73.92 (+1.56), OMER: 24.58 (+0.44)
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Pipeline Review, H2 2014 - 27 Companies & 49 Drug Profiles
M2 - Mon Nov 03, 8:36AM CST
Research and Markets (http://www.researchandmarkets.com/research/3gdhmp/attention_deficit) has announced the addition of the "Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD) and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Involved in Therapeutics Development - DURECT Corporation - Eli Lilly and Company - Taisho Pharmaceutical Co., Ltd. - NeuroDerm Ltd. - Takeda Pharmaceutical Company Limited - Richter Gedeon Nyrt. - Pfizer Inc. - Purdue Pharma L.P. - Shire Plc - Vernalis plc - Collegium Pharmaceutical, Inc. - Hisamitsu Pharmaceutical Co., Inc. - Arbor Pharmaceuticals, LLC. - Curemark, LLC - Supernus Pharmaceuticals, Inc. - Intra-Cellular Therapies, Inc. - Tris Pharma, Inc. - Neos Therapeutics, Inc. - KemPharm, Inc. - Otsuka Holdings Co., Ltd. - Reviva Pharmaceuticals Inc. - Amarantus Bioscience Holdings, Inc. - Mnemosyne Pharmaceuticals, Inc. - Alcobra Ltd - Sunovion Pharmaceuticals Inc. - Signature Therapeutics, Inc - P2D Bioscience For more information visit http://www.researchandmarkets.com/research/3g...on_deficit
ADHD: 5.70 (+0.20), PFE: 35.44 (+0.41), SUPN: 12.84 (+0.34), LLY: 73.92 (+1.56), DRRX: 1.98 (+0.08), NDRM: 13.93 (-0.25), SHPG: 248.77 (-5.55), ITCI: 23.98 (+0.15)
Global Psychosis Clinical Trials Review, H2, 2014
M2 - Tue Oct 28, 5:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/q3lmd7/psychosis_global) has announced the addition of the "Psychosis Global Clinical Trials Review, H2, 2014" report to their offering. Psychosis Global Clinical Trials Review, H2, 2014 provides elemental information and data relating to the clinical trials on Psychosis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Psychosis. Reasons to buy - Understand the dynamics of a particular indication in a condensed manner - Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more - Obtain discontinued trial listing for trials across the globe - Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies Top Companies Participating in Psychosis Therapeutics Clinical Trials - Johnson & Johnson - AstraZeneca PLC - Eli Lilly and Company - Pfizer Inc. - Otsuka Holdings Co., Ltd. - ZonMw - North Shore-Long Island Jewish Health System, Inc. - Acadia Pharmaceuticals Inc. Clinical Trial Overview of Top Institutes / Government - Department of Health, South Africa - Yale University - U.S. Department of Veterans Affairs - The University of Hong Kong - Maastricht University - Centre for Addiction and Mental Health - University of British Columbia - Melbourne Health - University of Cologne - New York State Psychiatric Institute For more information visit http://www.researchandmarkets.com/research/q3...sis_global
JNJ: 102.06 (+0.73), ACAD: 37.53 (+2.42), PFE: 35.44 (+0.41), AZN: 69.91 (-0.25), LLY: 73.92 (+1.56)
Global Schizoaffective Disorder Clinical Trials Report H2, 2014
M2 - Tue Oct 28, 5:01AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3w59x2/schizoaffective) has announced the addition of the "Schizoaffective Disorder Global Clinical Trials Review, H2, 2014" report to their offering. Schizoaffective Disorder Global Clinical Trials Review, H2, 2014" provides data on the Schizoaffective Disorder clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Schizoaffective Disorder. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Schizoaffective Disorder. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies - Johnson & Johnson - Pfizer Inc. - Eli Lilly and Company - AstraZeneca PLC - Bristol-Myers Squibb Company - Sumitomo Dainippon Pharma Co., Ltd. - Otsuka Holdings Co., Ltd. - AbbVie Inc. - North Shore-Long Island Jewish Health System, Inc. - Merck & Co., Inc. Top Institutes / Government - U.S. Department of Veterans Affairs - University of Maryland - University of Pittsburgh - Yale University - Centre for Addiction and Mental Health - National Institute of Mental Health - Vanderbilt University - Dartmouth-Hitchcock Medical Center - Massachusetts General Hospital - North Suffolk Mental Health Association For more information visit http://www.researchandmarkets.com/research/3w...oaffective
JNJ: 102.06 (+0.73), PFE: 35.44 (+0.41), MRK: 57.25 (-0.18), AZN: 69.91 (-0.25), LLY: 73.92 (+1.56), ABBV: 62.00 (+1.68), BMY: 64.64 (+1.18)
Global Open-Angle Glaucoma Therapeutics Pipeline Review 2014 - 22 Drug Profiles from 11 Companies
M2 - Fri Sep 12, 3:36AM CDT
Research and Markets (http://www.researchandmarkets.com/research/c97xhn/openangle) has announced the addition of the "Open-Angle Glaucoma - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Open-Angle Glaucoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Open-Angle Glaucoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - F. Hoffmann-La Roche Ltd. - Bausch & Lomb Incorporated - Santen Pharmaceutical Co., Ltd. - Oxford BioMedica plc - Sylentis S.A. - Ono Pharmaceutical Co., Ltd. - Asahi Kasei Pharma Corp. - Inotek Pharmaceuticals Corporation - Aerie Pharmaceuticals, Inc. - Otsuka Holdings Co., Ltd. - Amakem NV Drug Profiles - tafluprost - (tafluprost timolol maleate) - latanoprostene bunod - latanoprost - OPC-1085EL - trabodenoson - SYL-040012 - RO-5093151 - latanoprost - AR-13324 - AMA-0076 - ONO-9054 - ATS-907 - DE-117 - (latanoprost dorzolamide) - LX-7101 - HPP-851 - OPA-6566 - latanoprost SR - Glaucoma-GT - ATS-8535 - Small Molecule for Glaucoma For more information visit http://www.researchandmarkets.com/research/c97xhn/openangle
AERI: 32.30 (+0.14)
ReCor Medical Announces New Lead Investor and Upcoming Hypertension Trial
PR Newswire Europe - Fri Apr 10, 12:54PM CDT
ReCor Medical, Inc., a Palo Alto- and Amsterdam-based medical device firm, announced today a Series D investment of approximately $15M led by Otsuka Holdings Co., Ltd., the parent company of Otsuka Pharmaceutical and the Otsuka group of healthcare companies. Otsuka Holdings, one of the leading healthcare groups in Japan, joined Sofinnova Partners in the Series D round. In addition, ReCor has met with the US FDA regarding a new randomized controlled trial of its Paradise Renal Denervation ("RDN"
System in hypertensive patients to demonstrate its effect on blood pressure in conjunction with, and in the absence of, hypertensive drug therapy. The Company is planning to conduct the new study at 20 - 25 sites in the US and EU. BSX: 18.10 (unch)
Is Biogen A Buy? An Analysis Of Its Growth Drivers And Challenges
DoctoRx - at Seeking Alpha - Thu Apr 09, 12:28AM CDT
BIIB: 425.65 (-0.98), MDCO: 28.31 (+0.49), GILD: 101.77 (+0.61), MRK: 57.25 (-0.18), AZN: 69.91 (-0.25), LLY: 73.92 (+1.56), ABBV: 62.00 (+1.68), CELG: 117.07 (+1.49)
Polycystic Kidney Disease Global Clinical Trials Review, H1, 2015
M2 - Tue Mar 31, 4:15AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zf6s4z/polycystic_kidney) has announced the addition of the "Polycystic Kidney Disease Global Clinical Trials Review, H1, 2015" report to their offering. Polycystic Kidney Disease Global Clinical Trials Review, H1, 2015" provides data on the Polycystic Kidney Disease clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Polycystic Kidney Disease. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Polycystic Kidney Disease. Reasons to buy - Understand the dynamics of a particular indication in a condensed manner - Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more - Obtain discontinued trial listing for trials across the globe - Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies Top Companies Participating in Polycystic Kidney Disease Therapeutics Clinical Trials - Otsuka Holdings Co., Ltd. - Pfizer Inc. - Kadmon Corporation, LLC - Daiichi Sankyo Company, Limited - XORTX Pharma Corp. - Novartis AG - GLG Pharma LLC For more information visit http://www.researchandmarkets.com/research/zf...tic_kidney
PFE: 35.44 (+0.41), NVS: 103.58 (+1.01)
Type 1 Diabetes, Progress With Stem Cells And Other Cell-Based Therapies
Keith Williams - at Seeking Alpha - Mon Mar 30, 2:05PM CDT
NVO: 55.94 (+1.34), AZN: 69.91 (-0.25), BMY: 64.64 (+1.18)
2015 could be the year of the blockbuster drug
Seeking Alpha - at Seeking Alpha - Mon Mar 23, 3:26PM CDT
VRTX: 128.47 (+2.83), PFE: 35.44 (+0.41), AMGN: 163.38 (+1.89), BMY: 64.64 (+1.18), GSK: 48.23 (+0.51), GILD: 101.77 (+0.61), MRK: 57.25 (-0.18), ABBV: 62.00 (+1.68), THRX: 17.13 (+0.37), SNY: 52.35 (+0.48), REGN: 461.39 (+6.35), NVS: 103.58 (+1.01)
CHMP supports approval of Otsuka kidney disease drug
Seeking Alpha - at Seeking Alpha - Fri Feb 27, 10:19AM CST
Glaucoma Therapeutic Pipeline Companies and Drugs Review H1 2015 Report at RnRMarketResearch.com
PRWeb - Sun Jan 25, 11:30AM CST
The report "Glaucoma - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Glaucoma. Glaucoma is caused because of the pressure inside the eye. The primary function of the optic nerve is to send images to the brain. Permanent loss of vision can occur if this optic nerve gets damaged. If not treated on time total permanent blindness might occur. Proper precautions (like visiting an eye doctor) must be taken. The disease can be inherited and if any member of the family is found to be having glaucoma then immediately go for checking. Complete Report is Available @ http://www.rnrmarketresearch.com/glaucoma-pip...eport.html .
OCAT: 6.63 (-0.03), ITEK: 5.12 (-0.09), NBS: 2.98 (+0.06), FOMX: 9.87 (+0.45), AERI: 32.30 (+0.14), OCUL: 26.99 (-1.55), AGN: 240.22 (+2.88), CANF: 2.18 (+0.07), ACAD: 37.53 (+2.42), GILD: 101.77 (+0.61), MRK: 57.25 (-0.18), TEVA: 66.37 (-0.77), OHRP: 2.80 (+0.11), CBMG: 28.95 (+1.47)
Autism Therapeutic Pipeline Drugs and Companies Review H1 2015 Report at RnRMarketResearch.com
PRWeb - Fri Jan 23, 6:36AM CST
The report "Autism - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Autism. Autism is known as a multifarious developmental disability. Autism disorder is characterized by social activities, non-verbal communication and repetitive behavior. Autism is highly transmissible but the cause includes both environmental factors and genetic susceptibility. It has long been assumed that there is a common cause at the genetic, cognitive and neural levels for autism's characteristic triad of symptoms. The report enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Complete Report is Available @ http://www.rnrmarketresearch.com/autism-pipel...eport.html .
TEVA: 66.37 (-0.77), ITCI: 23.98 (+0.15), BCLI: 4.63 (+0.31), OMER: 24.58 (+0.44), NVS: 103.58 (+1.01)
Avanir's Drug-Device Combo Experiencing Minor FDA Headaches
Beacon VP Investments - at Seeking Alpha - Mon Dec 22, 1:41PM CST
AVNR: 16.96 (unch)
New Bidders Can Bring You High Return: Otsuka To Acquire Avanir
Maudes Capital - at Seeking Alpha - Tue Dec 02, 12:51PM CST
AVNR: 16.96 (unch)
Otsuka to buy US drugmaker Avanir for $3.5B
By The Associated Press - AP - Tue Dec 02, 6:06AM CST
Otsuka Pharmaceutical will spend $3.5 billion in cash to buy Avanir Pharmaceuticals in a deal that expands the Japanese drugmaker's portfolio of neurologic disease treatments.
AVNR: 16.96 (unch)
Wall Street Breakfast: Apple Heads To Trial Over iTunes Update
Wall Street Breakfast - Seeking Alpha - Tue Dec 02, 5:32AM CST
Economy Chinese stocks staged a late rally today amid speculation of more stimulus from the country's central bank. The Shanghai Composite Index climbed 3.1% , while the Hang Seng benchmark rose 1.2% . Oil has resumed declines as commodity...
VTNR: 2.58 (+0.03), MDT: 77.93 (+0.80), AV: 16.35 (+0.03), TFM: 41.47 (+0.47), GLW: 22.42 (+0.18), BA: 154.38 (+0.96), PCLN: 1,189.50 (+3.50), AVNR: 16.96 (unch), PERY: 24.56 (-0.01), SPY: 210.04 (+1.14), QQQ: 107.75 (+0.44), MSFT: 41.72 (+0.24), HMC: 34.66 (+0.58), AAPL: 127.10 (+0.54), HLSS: 17.18 (+0.01)
Otsuka to acquire Avanir for $17/share
Seeking Alpha - at Seeking Alpha - Tue Dec 02, 2:44AM CST
AVNR: 16.96 (unch)
Global Chronic Kidney Disease (Chronic Renal Failure) Therapeutics Pipeline Report H2 2014 - Analysis of 27 Companies & 39 Drug Profiles
M2 - Mon Nov 10, 10:32AM CST
Research and Markets (http://www.researchandmarkets.com/research/n5l8s3/chronic_kidney) has announced the addition of the "Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Kidney Disease (Chronic Renal Failure), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Kidney Disease (Chronic Renal Failure) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Hospira, Inc. - AstraZeneca PLC - Eli Lilly and Company - Quark Pharmaceuticals, Inc. - Astellas Pharma Inc. - OPKO Health, Inc. - Toray Industries, Inc. - Evotec AG - NPS Pharmaceuticals, Inc. - La Jolla Pharmaceutical Company - Alexion Pharmaceuticals, Inc. - AFFiRiS AG - Acceleron Pharma, Inc. - Nippon Zoki Pharmaceutical Co., Ltd. - Catabasis Pharmaceuticals, Inc. - Angion Biomedica Corp. - Concert Pharmaceuticals, Inc. - Intercept Pharmaceuticals, Inc. - Vitae Pharmaceuticals, Inc. - TRACON Pharmaceuticals, Inc. - Stelic Institute & Co. - Vicore Pharma AB - Otsuka Holdings Co., Ltd. - Sphaera Pharma Pvt. Ltd. - Multi Gene Vascular Systems Ltd - Bio-inRen - Red Glead Discovery AB For more information visit http://www.researchandmarkets.com/research/n5...nic_kidney
VTAE: 15.57 (+0.06), LLY: 73.92 (+1.56), CNCE: 14.71 (-0.41), OPK: 14.25 (-0.01), AZN: 69.91 (-0.25), ALXN: 182.68 (+5.31), ICPT: 279.25 (+7.48), NPSP: 45.97 (+0.01), XLRN: 34.23 (+0.15)
Global Bipolar Disorder (Manic Depression) Therapeutics Pipeline Review, H2 2014 - 22 Companies & 30 Drug Profiles
M2 - Thu Nov 06, 3:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/6grxbp/bipolar_disorder) has announced the addition of the "Bipolar Disorder (Manic Depression) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Bipolar Disorder (Manic Depression), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bipolar Disorder (Manic Depression) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AstraZeneca PLC - Eli Lilly and Company - Sumitomo Dainippon Pharma Co., Ltd. - Takeda Pharmaceutical Company Limited - Zogenix, Inc. - Richter Gedeon Nyrt. - Pfizer Inc. - Teva Pharmaceutical Industries Limited - Transition Therapeutics Inc. - Intas Pharmaceuticals Ltd. - D-Pharm Ltd. - Omeros Corporation - Intra-Cellular Therapies, Inc. - KemPharm, Inc. - Ascendis Pharma A/S - Otsuka Holdings Co., Ltd. - Reviva Pharmaceuticals Inc. - MarcoPolo Pharmaceuticals SA - Delpor, Inc. - Zysis Limited - Convergence Pharmaceuticals Ltd. - SK Biopharmaceuticals Co., Ltd. Drug Profiles - aripiprazole - quetiapine fumarate ER - ramelteon - ELND-005 - ziprasidone hydrochloride - cariprazine - YKP-3089 - Endoxifen - ITI-007 - DP-VPA - LY-2979165 - risperidone - Drug for Cancer and Neurodegenerative Disease - aripiprazole CR - lurasidone hydrochloride - SKL-PSY - Small Molecule To Antagonize GPR78 for Bipolar Disorder and Schizophrenia - NP-202 - ACP-005 - Small Molecule to Target GPR50 for CNS and Metabolic Disorders - risperidone - paliperidone - CNV-1061436 - PGW-5 - KP-303 - MP-03 - Small Molecules to Antagonize NMDA Receptor and CHRNA7 for CNS - Synthetic Peptides to inhibit IMPase for Bipolar Disorder - BRDK-98958073 - RP-5063 For more information visit http://www.researchandmarkets.com/research/6g...r_disorder
ZGNX: 1.49 (+0.01), PFE: 35.44 (+0.41), AZN: 69.91 (-0.25), TTHI: 6.99 (+0.08), TEVA: 66.37 (-0.77), ITCI: 23.98 (+0.15), LLY: 73.92 (+1.56), OMER: 24.58 (+0.44)
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Pipeline Review, H2 2014 - 27 Companies & 49 Drug Profiles
M2 - Mon Nov 03, 8:36AM CST
Research and Markets (http://www.researchandmarkets.com/research/3gdhmp/attention_deficit) has announced the addition of the "Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD) and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Involved in Therapeutics Development - DURECT Corporation - Eli Lilly and Company - Taisho Pharmaceutical Co., Ltd. - NeuroDerm Ltd. - Takeda Pharmaceutical Company Limited - Richter Gedeon Nyrt. - Pfizer Inc. - Purdue Pharma L.P. - Shire Plc - Vernalis plc - Collegium Pharmaceutical, Inc. - Hisamitsu Pharmaceutical Co., Inc. - Arbor Pharmaceuticals, LLC. - Curemark, LLC - Supernus Pharmaceuticals, Inc. - Intra-Cellular Therapies, Inc. - Tris Pharma, Inc. - Neos Therapeutics, Inc. - KemPharm, Inc. - Otsuka Holdings Co., Ltd. - Reviva Pharmaceuticals Inc. - Amarantus Bioscience Holdings, Inc. - Mnemosyne Pharmaceuticals, Inc. - Alcobra Ltd - Sunovion Pharmaceuticals Inc. - Signature Therapeutics, Inc - P2D Bioscience For more information visit http://www.researchandmarkets.com/research/3g...on_deficit
ADHD: 5.70 (+0.20), PFE: 35.44 (+0.41), SUPN: 12.84 (+0.34), LLY: 73.92 (+1.56), DRRX: 1.98 (+0.08), NDRM: 13.93 (-0.25), SHPG: 248.77 (-5.55), ITCI: 23.98 (+0.15)
Global Psychosis Clinical Trials Review, H2, 2014
M2 - Tue Oct 28, 5:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/q3lmd7/psychosis_global) has announced the addition of the "Psychosis Global Clinical Trials Review, H2, 2014" report to their offering. Psychosis Global Clinical Trials Review, H2, 2014 provides elemental information and data relating to the clinical trials on Psychosis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Psychosis. Reasons to buy - Understand the dynamics of a particular indication in a condensed manner - Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more - Obtain discontinued trial listing for trials across the globe - Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies Top Companies Participating in Psychosis Therapeutics Clinical Trials - Johnson & Johnson - AstraZeneca PLC - Eli Lilly and Company - Pfizer Inc. - Otsuka Holdings Co., Ltd. - ZonMw - North Shore-Long Island Jewish Health System, Inc. - Acadia Pharmaceuticals Inc. Clinical Trial Overview of Top Institutes / Government - Department of Health, South Africa - Yale University - U.S. Department of Veterans Affairs - The University of Hong Kong - Maastricht University - Centre for Addiction and Mental Health - University of British Columbia - Melbourne Health - University of Cologne - New York State Psychiatric Institute For more information visit http://www.researchandmarkets.com/research/q3...sis_global
JNJ: 102.06 (+0.73), ACAD: 37.53 (+2.42), PFE: 35.44 (+0.41), AZN: 69.91 (-0.25), LLY: 73.92 (+1.56)
Global Schizoaffective Disorder Clinical Trials Report H2, 2014
M2 - Tue Oct 28, 5:01AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3w59x2/schizoaffective) has announced the addition of the "Schizoaffective Disorder Global Clinical Trials Review, H2, 2014" report to their offering. Schizoaffective Disorder Global Clinical Trials Review, H2, 2014" provides data on the Schizoaffective Disorder clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Schizoaffective Disorder. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Schizoaffective Disorder. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies - Johnson & Johnson - Pfizer Inc. - Eli Lilly and Company - AstraZeneca PLC - Bristol-Myers Squibb Company - Sumitomo Dainippon Pharma Co., Ltd. - Otsuka Holdings Co., Ltd. - AbbVie Inc. - North Shore-Long Island Jewish Health System, Inc. - Merck & Co., Inc. Top Institutes / Government - U.S. Department of Veterans Affairs - University of Maryland - University of Pittsburgh - Yale University - Centre for Addiction and Mental Health - National Institute of Mental Health - Vanderbilt University - Dartmouth-Hitchcock Medical Center - Massachusetts General Hospital - North Suffolk Mental Health Association For more information visit http://www.researchandmarkets.com/research/3w...oaffective
JNJ: 102.06 (+0.73), PFE: 35.44 (+0.41), MRK: 57.25 (-0.18), AZN: 69.91 (-0.25), LLY: 73.92 (+1.56), ABBV: 62.00 (+1.68), BMY: 64.64 (+1.18)
Global Open-Angle Glaucoma Therapeutics Pipeline Review 2014 - 22 Drug Profiles from 11 Companies
M2 - Fri Sep 12, 3:36AM CDT
Research and Markets (http://www.researchandmarkets.com/research/c97xhn/openangle) has announced the addition of the "Open-Angle Glaucoma - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Open-Angle Glaucoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Open-Angle Glaucoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - F. Hoffmann-La Roche Ltd. - Bausch & Lomb Incorporated - Santen Pharmaceutical Co., Ltd. - Oxford BioMedica plc - Sylentis S.A. - Ono Pharmaceutical Co., Ltd. - Asahi Kasei Pharma Corp. - Inotek Pharmaceuticals Corporation - Aerie Pharmaceuticals, Inc. - Otsuka Holdings Co., Ltd. - Amakem NV Drug Profiles - tafluprost - (tafluprost timolol maleate) - latanoprostene bunod - latanoprost - OPC-1085EL - trabodenoson - SYL-040012 - RO-5093151 - latanoprost - AR-13324 - AMA-0076 - ONO-9054 - ATS-907 - DE-117 - (latanoprost dorzolamide) - LX-7101 - HPP-851 - OPA-6566 - latanoprost SR - Glaucoma-GT - ATS-8535 - Small Molecule for Glaucoma For more information visit http://www.researchandmarkets.com/research/c97xhn/openangle
AERI: 32.30 (+0.14)
